ArticleFrontiers in oncology2021
Muscle Loss During Androgen Deprivation Therapy Is Associated With Higher Risk of Non-Cancer Mortality in High-Risk Prostate Cancer.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Guideline
- Influence of Androgen Deprivation Therapy on the Development of Sarcopenia in Patients with Prostate Cancer: A Systematic Review.Nutrients · 2024Pooled it
- HyperSightRadiation oncology (London, England) · 2026Article
- Article
- Prognostic value of body composition out of PSMA-PET/CT in prostate cancer patients undergoing PSMA-therapy.European journal of nuclear medicine and molecular imaging · 2025Article
- Assessing body composition using auto-segmentations of muscle and subcutaneous adipose tissue in prostate cancer patients receiving magnetic resonance-guided radiotherapy.Physics and imaging in radiation oncology · 2025Article
- Androgen Deprivation Therapy-Induced Muscle Loss and Fat Gain Predict Cardiovascular Events in Prostate Cancer Patients.Journal of cachexia, sarcopenia and muscle · 2025Article
- A Patient-Specific, Goal-Oriented Exercise Algorithm for Men Receiving Androgen Deprivation Therapy.Clinical journal of oncology nursing · 2025Article
- Skeletal Muscle Loss During Treatment With Abiraterone in Patients With Metastatic Prostate Cancer.Prostate cancer · 2025Article
- Influence of androgen deprivation therapy on physical performance and muscle strength in prostate cancer patients - a systematic review.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2025Review
- Sarcopenia and lower urinary tract diseases: links, mechanisms, and clinical implications.Frontiers in nutrition · 2025Review
- Design of debunking the frailty-sarcopenia-ADT axis in metastatic prostate cancer with multicomponent exercise: the FIERCE trial protocol.Frontiers in sports and active living · 2025Article
- Thresholds of Body Composition Changes Associated with Survival During Androgen Deprivation Therapy in Prostate Cancer.European urology open science · 2024Article
- Body Composition During Androgen Deprivation Therapy in Prostate Cancer: A Target to Reduce Cardiovascular Risk.JACC. CardioOncology · 2024Article
- Cancer Therapy and Exercise Intolerance: The Heart Is But a Part:JACC. CardioOncology · 2024Review
- Interpretable machine learning model based on clinical factors for predicting muscle radiodensity loss after treatment in ovarian cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Low Alanine Aminotransferase, as a Marker of Sarcopenia and Frailty, Is Associated with Shorter Survival Among Prostate Cancer Patients and Survivors. A Retrospective Cohort Analysis of 4064 Patients.European urology open science · 2023Article
- Body composition parameters were associated with response to abiraterone acetate and prognosis in patients with metastatic castration-resistant prostate cancer.Cancer medicine · 2023Article
- Effects of walking football on adherence, safety, quality of life and physical fitness in patients with prostate cancer: Findings from the PROSTATA_MOVE randomized controlled trial.Frontiers in oncology · 2023Article
- Muscle wasting assessment tools for prostate cancer.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The changes in body composition are early adverse effects of androgen deprivation therapy (ADT); however, their prognostic impact remains unclear in prostate cancer. This study aimed to evaluate the association between body composition changes and survival in patients with high-risk prostate cancer. We measured the skeletal muscle index (SMI) and total adipose tissue index (TATI) at the L3 vertebral level using computed tomography at baseline and within one year after initiating ADT in 125 patients with high-risk prostate cancer treated with radiotherapy and ADT between 2008 and 2018. Non-cancer mortality predictors were identified using Cox regression models. The median follow-up was 49 months. Patients experienced an average SMI loss of 5.5% over 180 days (95% confidence interval: -7.0 to -4.0;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.